Swiss Nordic Bio 2018
OFFER: Free of charge for the first 10 West Swedish companies that register. Contact us and ask for your promotion code!
Why Swiss Nordic Bio?
- Exclusive event with maximum 200 participants in total where all participants are screened before being granted access to the conference
- Spot the latest Nordic life science innovations at the pitching session from upcoming Nordic biotech/medtech SME’s
- Discuss potential collaboration and partnering opportunities in 1-to-1 meetings with upcoming Nordic biotech/medtech SME’s, big pharma as well as industry peers
- Learn more about the possibilities for R&D collaboration between SME’s, large corporations and academia directly from EUREKA-Eurostars decision makers
Who has attended Swiss Nordic Bio?
HBM Partners, Bay City Capital, Seventure Partner, HealthCap, Sunstone Capital, NovoSeeds, Capital Rewards Partners, Index Ventures, Creathor Venture, Alden Impact Capital, Occident Group, Redalpine Venture Partners, Johnson & Johnson Innovation, AGIRE Foundation, Industrifonden, Boehringer Ingelheim Venture Fund, PM Equity Partner, XOVenture, Novartis Venture Fund, Roche, Novo Nordisk, Debiopharm, Vifor Pharma, Endeavour Vision SA, Merck Ventures BV, Novo A/S (Ventures), Debiopharm International SA.
Registration closes on 2 February 2018.
For more information and to register, please visit: swissnordicbio.com. If you have any further questions, please contact:
Edin Erkocevic Project Manager, Business Sweden
T: +43 664 235 15 25
Iris Öhrn, Life Science Investment Advisor, Business Region Göteborg
T: +46 313 67 61 30